Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal fibrosing lung disease of unknown cause. The advent of anti-fibrotic medications known to slow disease progression has revolutionised IPF management in recent years. However, little is known about the natural history of IPF patients with mild physiological impairment. We aimed to assess the natural history of these patients using data from the Australian IPF Registry (AIPFR). METHODS: Using our cohort of real-world IPF patients, we compared FVC criteria for mild physiological impairment (FVC ≥ 80%) against other proposed criteria: DLco ≥ 55%; CPI ≤40 and GAP stage 1 with regards agreement in classification and relationship with disease outcomes. Within the mild cohort (FVC ≥ 80%), we also explored markers associated with poorer prognosis at 12 months. RESULTS: Of the 416 AIPFR patients (mean age 70.4 years, 70% male), 216 (52%) were classified as 'mild' using FVC ≥ 80%. There was only modest agreement between FVC and DLco (k = 0.30), with better agreement with GAP (k = 0.50) and CPI (k = 0.48). Patients who were mild had longer survival, regardless of how mild physiologic impairment was defined. There was, however, no difference in the annual decline in FVC% predicted between mild and moderate-severe groups (for all proposed criteria). For patients with mild impairment (n = 216, FVC ≥ 80%), the strongest predictor of outcomes at 12 months was oxygen desaturation on a 6 min walk test. CONCLUSION: IPF patients with mild physiological impairment have better survival than patients with moderate-severe disease. Their overall rate of disease progression however, is comparable, suggesting that they are simply at different points in the natural history of IPF disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recently, the Composite Physiologic Index (CPI) and the Gender-Age-Physiology (GAP) index have been most commonly applied for estimating the survival of patients with IPF [3–6].”
From Comparison of disease progression subgroups in idiopathic pulmonary fibrosis (2019) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Self-citationA Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis
Ley, B., Ryerson, C. J., Vittinghoff, E., Ryu, J. H., Tomassetti, S., Lee, J. S., Poletti, V., Buccioli, M., Elicker, B. M., Jones, K. D., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-10-201205150-00004 · Cited by 1,308
Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review
Hutchinson, J., Fogarty, A., Hubbard, R., & McKeever, T. (2015) · European Respiratory Journal · doi:10.1183/09031936.00185114 · Cited by 913
Predicting Survival in Idiopathic Pulmonary Fibrosis
KING, T. E., TOOZE, J. A., SCHWARZ, M. I., BROWN, K. R., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.7.2003140 · Cited by 853
Wells, A. U., Desai, S. R., Rubens, M. B., Goh, N. S. L., Cramer, D., Nicholson, A. G., Colby, T. V., du Bois, R. M., & Hansell, D. M. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2111053 · Cited by 686 · cited 12×
“Physiologic measurements, such as FVC or diffusion capacity for carbon monoxide (DLco) have been commonly used [12, 13], as have composite measures of several physiologic values or demographic features [14, 15].”
BackgroundMethodSelf-citationNoble, P. W., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Fagan, E. A., Fishman, R. S., Glaspole, I., Glassberg, M. K., Lancaster, L., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00026-2015 · Cited by 468
Self-citationRicheldi, L., Cottin, V., du Bois, R. M., Selman, M., Kimura, T., Bailes, Z., Schlenker-Herceg, R., Stowasser, S., & Brown, K. K. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.02.001 · Cited by 463
Six-Minute-Walk Distance Predicts Waiting List Survival in Idiopathic Pulmonary Fibrosis
Lederer, D. J., Arcasoy, S. M., Wilt, J. S., D'Ovidio, F., Sonett, J. R., & Kawut, S. M. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200604-520oc · Cited by 402
Cited by
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Maher, T. M., & Strek, M. E. (2019) · Respiratory Research · doi:10.1186/s12931-019-1161-4 · Cited by 265
Kreuter, M., Swigris, J., Pittrow, D., Geier, S., Klotsche, J., Prasse, A., Wirtz, H., Koschel, D., Andreas, S., Claussen, M., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1020-3 · Cited by 125
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
Richeldi, L., Kolb, M., Jouneau, S., Wuyts, W. A., Schinzel, B., Stowasser, S., Quaresma, M., & Raghu, G. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-1030-4 · Cited by 96
Wuyts, W. A., Wijsenbeek, M., Bondue, B., Bouros, D., Bresser, P., Robalo Cordeiro, C., Hilberg, O., Magnusson, J., Manali, E. D., Morais, A., et al. (2020) · Respiration · doi:10.1159/000504763 · Cited by 96
on behalf of the IPF-PRO™ Registry investigators, Snyder, L., Neely, M. L., Hellkamp, A. S., O’Brien, E., de Andrade, J., Conoscenti, C. S., Leonard, T., Bender, S., Gulati, M., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1043-9 · Cited by 85
Metadata
- Authors
- Jo, H. E., Glaspole, I., Moodley, Y., Chapman, S., Ellis, S., Goh, N., Hopkins, P., Keir, G., Mahar, A., Cooper, W., Reynolds, P., Haydn Walters, E., Zappala, C., Grainge, C., Allan, H., Macansh, S., & Corte, T. J.
- Affiliations
- The University of Sydney (AU)
- The Alfred Hospital (AU)
- Fiona Stanley Hospital (AU)
- Royal Adelaide Hospital (AU)
- Austin Hospital (AU)
- Prince Charles Hospital (AU)
- Royal Prince Alfred Hospital (AU)
- Royal Brisbane and Women's Hospital (AU)
- John Hunter Hospital (AU)
- Lung Foundation Australia (AU)
- Corresponding author
- Jo, Helen E.
- ORCID
- Venue
- BMC Pulmonary Medicine
- Published
- 2018-01-25
- Volume
- 18
- Issue
- 1
- Pages
- 19-19
- ISSN
- 1471-2466 (ISSN-L)
- PMC
- PMC5785886
- OpenAlex
- W2787279971
- Cited by
- 77
- References
- 22
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 4 · 2023: 8 · 2022: 10 · 2021: 11 · 2020: 16 · 2019: 14 · 2018: 3
- FWCI
- 8.29
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- BMC Pulmonary Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UTAS Research Repository (acceptedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, cc-by)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Health and Medical research Council (APP1066128)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- idiopathic pulmonary fibrosis, natural history (disease), disease progression, forced vital capacity, diffusing capacity for carbon monoxide, chronic respiratory failure, prognosis, survival, oxygen desaturation, 6-minute walk test, antifibrotic therapy
- MeSH terms
- Walk Test, Age Factors, Aged, Australia, Carbon Monoxide, Female, Humans, Male, Middle Aged, Oxygen, Pulmonary Diffusing Capacity, Registries, Severity of Illness Index, Sex Factors, Smoking, Vital Capacity, Body Mass Index, Disease Progression, Idiopathic Pulmonary Fibrosis, Symptom Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. https://app.cochat.ai/papers/10.1186/s12890-018-0575-y
- The paper
- Jo, H. E., Glaspole, I., Moodley, Y., Chapman, S., Ellis, S., Goh, N., Hopkins, P., Keir, G., Mahar, A., Cooper, W., Reynolds, P., Haydn Walters, E., Zappala, C., Grainge, C., Allan, H., Macansh, S., & Corte, T. J. (2018). Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. BMC Pulmonary Medicine. https://doi.org/10.1186/s12890-018-0575-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.